Member Info for Laura2022

Kidlington,as msuk sas its people who probably bought due to VAL yesterday and then selling for no reason

Alot of the volume today can be matched to yesterday

Thanks msuk

For a man of constant drive porky couldn't and didn't respond to this very simple question I asked of him last night

RE: VAL 201 £6mln to PYC2 Oct 2023 21:51

Porky

You can't and don't invest as you lost everything everything on DDDD hence why not once have you posted that you have purchased any single share In any company . Why did you lose it all on DDDD when the BOD were lying about their finances?...

Very odd you didn't see that coming

Instead you lurk on various chat board imparting nonsense

Again

Deal closing apparently

£1mln pipeline for this year alone with £850,000 cash as of annual report date amd a mere £2.5mln cap

Welcome Steve

PYC is at cutting edge of artificial intelligence in oncology and drug development

What it shows to me is while other companies are battoning down hatches PYC are expanding and growing ,these last 3 new appointment come with a good pedigree

And with a very healthy cash to market cap ratio of 1 : 3 and a growing pipeline with a record ever revenues expected in 2023/24 as stated in annual report

Update on ths sector "before the end of the calander year "

hiring this week of a new senior member of its team, Dr Venkata Putcha, as Head of Biostatistics.

 

Dr Putcha brings with him over 22 years of experience working within drug development, with over 17 years working for many of the top-tier pharmaceutical and CRO companies

The Head of Biostatistics role will help to formulate and deliver on the Company's new Biostatistics service offering. The initial focus will be to build upon the Company's existing Biostatistics strategy, working with Business Development and Senior Management to define key service offerings and identify new clients. Dr Putcha will be responsible for the delivery of new Biostatistics consulting contracts within the business and, as we grow this service line, will take a lead refining and executing on the Company's Biostatistics strategy.

 

Dr Jim Millen, Executive Chair and CEO commented:

 

"Following our announcement earlier this year that Physiomics would be expanding into adjacent areas of lifesciences R&D consulting, starting with biostatistics, we are delighted to welcome Venkata to our team.  His extensive experience in the field of biostatistics will act as a strong base from which to grow this new segment of our business.  We'll be providing a further update on our expansion into this field later this calendar year."

 

What don't hey class as that ?

The Company has also undertaken a detailed review of the ramp up and operational costs. The Company expects to publish an update by mid Q4-2023 once this review is complete.

Porky

You can't and don't invest as you lost everything everything on DDDD hence why not once have you posted that you have purchased any single share In any company . Why did you lose it all on DDDD when the BOD were lying about their finances?...

Very odd you didn't see that coming

Instead you lurk on various chat board imparting nonsense

The Company completed its observational "PARTNER" study at Portsmouth University Hospitals NHS Trust which validated the ability of the tool to predict levels of neutropenia. Although this was felt to be of interest by clinicians, it was determined that the tools use to guide the use of the expensive biological drug GCSF (used to counteract neutropenia) might have a higher commercial value and the Company is currently actively exploring ways to further develop its tool to facilitate this.

During the year, the Company's US partner DoseMeRx announced that it had been divested by its owner Tabula Rasa Healthcare (TRHC) and acquired by a private equity company. Since then, the Company has re-established contact with DoseMeRx and discussions are ongoing around how the Company's tool might be used in the US.

Ironmighty

Posts: 400

Price: 7.85

No Opinion

TheoremRx tweet 16.30Today 16:44

Https://x.com/patrickfrankham/status/1708867845336007065?s=46&t=xdsQNV0n_ZHRmadh3y3aIA

Patrick Frankham (CEO TheoremRx):

Taking biotech startups from concept to identifying suitable druggable assets to a risk adjusted portfolio to a fundable business case in todays macro-environment is challenging but still achievable in the US. #stealthmodebio

 appears that the 201 deal is about to be signed. That will bring significant payments. Also the lab is fully set up to bring in revenue generating contracts.

Worth watching the first 10 minutes of the presentation. TRX has now also made public the website

Up to £6mln due to PYC

£1mln pipeline for this year alone with £850,000 cash as of annual report date amd a mere £2.5mln cap

According to VAL Q and A it is close is close be being signed

Ignore porky

He lost £1000s on DDDD and NCYT and now spends 2yrs plaguing VAL board

Hi cypp

Ignore these lunatics and welcome on board

Good to have new investors like yourself

The sale price

Falling knife what a thoroughly unpleasant person, your friends and family mist be proud of you

At 70-71p

Where do people think it will bounce